I think you have hit the nub of the problem....Vascepa is purifed EPA...NOT a fish oil...When Vascepa is connected to a statin, it can seriously reduce the incidence of CVD...and OTHER DISEASES with an inflammatory element...This connection should be emphasized in PR's, in literature and in adds.
STATIN, ALONE WILL NOT DO THE JOB THAT STATIN PLUS VASCEPA WILL DO!!!
Thus far, Amatin has failed to make this connection in the minds of Docs or of patients.
Rose…i think you are on to something….the Pharma scientists/specialists are more knowledgeable than the Patent personnel and FDA..it is possible they think Amarin made a nice “discovery” with V but that it is really just part of the whole Omega 3/fish oil mindset with docs/patients….good drug but not patentable…patents didn’t hold in U.S. and probably won’t in the ROW…they figure Amarin couldn’t distinguish V from Lovaza/fish oil and good chance they couldn’t either without dropping price down below cost of production…i’ve got a big bet that Denner can solve this issue but i’m beginning to wonder if Denner might decide the only way to get his money back is by taking it private at a bargain price…
News 
Market Data 
Discover 
AI
